Gene Therapy Market
Gene Therapy Market Size, Share & Trends Analysis Report 2024-2030, By Indication, By Vector Type, By Route Of Administration, By Region and Segment Forecasts
20. August 2024 06:28 ET | Research and Markets
Dublin, Aug. 20, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type...
Adeno-associated Virus Gene Therapy Market
Adeno-associated Virus Gene Therapy Market Report 2024-2034: Epidemiology, Industry Trends and Forecasts
21. Juni 2024 06:05 ET | Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Adeno-associated Virus Gene Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been...
22157.jpg
AAV Vectors in Gene Therapy Pipeline Landscape Report 2024: Comprehensive Insights about 70+ Companies and 235+ Pipeline Drugs
19. April 2024 07:31 ET | Research and Markets
Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "AAV vectors in gene therapy - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "AAV vectors in gene...
22157.jpg
Global Cell and Gene Therapy Markets Report 2024-2028 Featuring Main Players - Mallinckrodt, Vericel, Gilead Sciences, Pharmicell, and Bristol-Myers Squibb
03. April 2024 03:10 ET | Research and Markets
Dublin, April 03, 2024 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering. The Global Cell and Gene Therapy Market is...
Roots-Analysis-Logo.png
The adeno associated viral vector / AAV vector market is anticipated to grow at a CAGR of more than 10% by 2035, claims Roots Analysis
27. Oktober 2022 12:38 ET | Roots Analysis
London, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Adeno Associated Viral Vector / AAV Vector Market, 2022-2035” report to its list of offerings. Owing to...
Asklepios BioPharmac
Asklepios BioPharmaceutical, Inc. Announces Former Portfolio Company’s Preclinical Asset for Duchenne Muscular Dystrophy Has Advanced into the Clinic
25. April 2018 08:05 ET | Asklepios BioPharmaceutical, Inc.
Pfizer, Inc. Dosed First Patient in its Mini-Dystrophin Gene Therapy Phase 1b Trial Another AskBio Platform Product to be Acquired by Big Pharma Novartis CHAPEL HILL, N.C., April 25, 2018 (GLOBE...